The European Commission has officially launched a public consultation on the EU Cardiovascular Health Plan—a long-anticipated and vital step forward in shaping the future of cardiovascular disease (CVD) prevention and care across the EU.
This is a historic opportunity for our community to ensure that inherited lipid disorders—including familial hypercholesterolaemia (FH), homozygous FH, elevated lipoprotein(a) [Lp(a)], and familial chylomicronaemia syndrome (FCS)—are fully recognised as major risk factors for cardiovascular disease in EU-level health policy.
The consultation is more than a formality—it’s a chance to influence the EU’s strategic direction on cardiovascular health. We must advocate for:
Over the years, FH Europe Foundation, in collaboration with our network of patients, clinicians, researchers, and policy advocates, has laid the groundwork for this moment. Key milestones include:
These achievements have helped build the momentum we now see reflected in this EU-level initiative.
The consultation is open until 15 September 2025 and is hosted on the European Commission’s platform (registration required). We encourage all stakeholders—patients, clinicians, researchers, and advocates—to participate and make their voices heard.
FH Europe Foundation is coordinating a comprehensive response, drawing on insights from our Network Leaders, Patient Ambassadors, Scientific Experts, and industry partners. Our submission will combine robust scientific evidence with the lived experiences of those affected by lipid conditions.
We will share our final position with the community to ensure transparency and alignment, and to empower others to advocate effectively.
Together, we can shape a Cardiovascular Health Plan that truly reflects the needs of our community.
📢 Join the consultation here
📅 Deadline: 15 September 2025